Inoue, Kenichi http://orcid.org/0000-0003-2686-8732
Nagai, Shigenori E.
Saito, Tsuyoshi
Sakurai, Takashi
Kimizuka, Kei
Yamada, Hirofumi
Kuroda, Toru
Hata, Satoshi
Yamazaki, Yasuo
Kojima, Masato
Futsuhara, Kazushige
,
Funding for this research was provided by:
Japan Agency for Medical Research and Development, AMED (18ck0106307h0002)
Article History
Received: 29 April 2019
Accepted: 1 July 2019
First Online: 10 July 2019
Compliance with ethical standards
:
: Dr. Inoue received grant from Novartis, Pfizer, Chugai, Daiichi-Sankyo, Parexel/Puma Biotechnology, MSD, Bayer, Lilly, and Eisai during the conduct of the study. The other authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: All patients provided written informed consent before enrollment. The study protocol was approved by the following ethics bodies: for Saitama Cancer Center, Institutional Review Board; and for Mitsui Hospital and Ina Hospital, Central Ethics Committee at Saitama Cancer Center.